Frontiers in Aging Neuroscience (Jul 2021)

Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome

  • Xu-Qiao Chen,
  • Zhuo Xing,
  • Quang-Di Chen,
  • Richard J. Salvi,
  • Xuming Zhang,
  • Benjamin Tycko,
  • Benjamin Tycko,
  • William C. Mobley,
  • Y. Eugene Yu,
  • Y. Eugene Yu

DOI
https://doi.org/10.3389/fnagi.2021.700280
Journal volume & issue
Vol. 13

Abstract

Read online

Down syndrome (DS) is the most common genetic cause of Alzheimer’s disease (AD) due to trisomy for all or part of human chromosome 21 (Hsa21). It is also associated with other phenotypes including distinctive facial features, cardiac defects, growth delay, intellectual disability, immune system abnormalities, and hearing loss. All adults with DS demonstrate AD-like brain pathology, including amyloid plaques and neurofibrillary tangles, by age 40 and dementia typically by age 60. There is compelling evidence that increased APP gene dose is necessary for AD in DS, and the mechanism for this effect has begun to emerge, implicating the C-terminal APP fragment of 99 amino acid (β-CTF). The products of other triplicated genes on Hsa21 might act to modify the impact of APP triplication by altering the overall rate of biological aging. Another important age-related DS phenotype is hearing loss, and while its mechanism is unknown, we describe its characteristics here. Moreover, immune system abnormalities in DS, involving interferon pathway genes and aging, predispose to diverse infections and might modify the severity of COVID-19. All these considerations suggest human trisomy 21 impacts several diseases in an age-dependent manner. Thus, understanding the possible aging-related mechanisms associated with these clinical manifestations of DS will facilitate therapeutic interventions in mid-to-late adulthood, while at the same time shedding light on basic mechanisms of aging.

Keywords